Pancreatic Cancer Research

ResearcherSanguine Diagnostics And TherapeuticsActive in the last 2 years

Maneesh Jain

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2020-3687; OpenAlex author ID A5090154787; NIH RePORTER profile ID 8895267. Sources: OpenAlex.

Their work

Papers
47 (first author 0, last author 8)
Trials
0
Grants
9
Labs led
1
Collaborators
145
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers, 1 grant · 2013: 2 papers · 2014: 1 paper · 2015: 5 papers, 1 grant · 2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper, 3 grants · 2020: 3 papers · 2021: 3 papers, 1 grant · 2022: 8 papers, 1 grant · 2023: 3 papers · 2024: 4 papers, 1 grant · 2025: 3 papers · 2026: 2 papers, 1 grant

Papers 47

  1. A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. Co-author DOI 10.1016/j.actbio.2026.04.026↗
  2. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  3. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/s41698-025-01046-w↗
  4. Mucin4 (MUC4) Antibody Labeled with an NIR Dye Brightly Targets Pancreatic Cancer Liver Metastases and Peritoneal Carcinomatosis. Co-author DOI 10.3390/cancers17122031↗
  5. Brightly Visualizing Pancreatic Cancer Margins in Orthotopic Mouse Models with an Anti-CA19-9 Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.3390/cancers17162617↗
  6. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Co-author DOI 10.1016/j.canlet.2024.217245↗
  7. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2024.101146↗
  8. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  9. Targeting Human Pancreatic Cancer with a Fluorophore-Conjugated Mucin 4 (MUC4) Antibody: Initial Characterization in Orthotopic Cell Line Mouse Models. Co-author DOI 10.3390/jcm13206211↗
  10. Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Co-author DOI 10.1038/s41388-022-02587-1↗
  11. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12943-023-01813-y↗
  12. MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1073820↗
  13. Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.215801↗
  14. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  15. Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. Co-author DOI 10.1016/j.semcancer.2022.08.009↗
  16. Regulation of pancreatic cancer therapy resistance by chemokines. Last author DOI 10.1016/j.semcancer.2022.08.010↗
  17. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  18. Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity. Co-author DOI 10.1053/j.gastro.2022.02.032↗
  19. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  20. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Last author DOI 10.7150/thno.64805↗
  21. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. Co-author DOI 10.1002/jbm.a.37080↗
  22. Modeling pancreatic cancer in mice for experimental therapeutics. Last author DOI 10.1016/j.bbcan.2021.188554↗
  23. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  24. Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). Co-author DOI 10.1016/j.bbcan.2019.188318↗
  25. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.smim.2020.101391↗
  26. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1096/fj.201902990r↗
  27. Label-free characterization of exosome via surface enhanced Raman spectroscopy for the early detection of pancreatic cancer. Co-author DOI 10.1016/j.nano.2018.11.008↗
  28. Emerging trends in the immunotherapy of pancreatic cancer. Last author DOI 10.1016/j.canlet.2017.12.012↗
  29. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Co-author DOI 10.18632/genesandcancer.171↗
  30. Biological determinants of radioresistance and their remediation in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2017.02.003↗
  31. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Co-author DOI 10.1038/ajg.2016.482↗
  32. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. Last author DOI 10.1080/14728222.2017.1323880↗
  33. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Co-author DOI 10.1016/j.biomaterials.2016.05.042↗
  34. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  35. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Co-author DOI 10.1038/onc.2014.154↗
  36. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Co-author DOI 10.1038/onc.2014.409↗
  37. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000362↗
  38. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.3912↗
  39. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Co-author DOI 10.1038/bjc.2014.385↗
  40. Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Last author DOI 10.1016/j.canlet.2013.07.037↗
  41. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055171↗
  42. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Co-author DOI 10.1093/carcin/bgs225↗
  43. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Co-author DOI 10.1186/1756-8722-5-68↗
  44. Early diagnosis of pancreatic cancer: challenges and new developments. Co-author DOI 10.2217/bmm.12.69↗
  45. Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. Co-author DOI 10.1021/ac102829b↗
  46. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Co-author DOI 10.1038/bjc.2011.31↗
  47. Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0023344↗

Grants 9

  1. Lysosome Trapped FAP-Targeted Theranostics for Pancreatic Cancer R01CA290859↗
  2. Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer R01CA247471↗
  3. Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis P01CA217798↗
  4. Nanovaccine platforms to combat pancreatic cancer U01CA213862↗
  5. Targeted Radiation Therapy for Pancreatic Cancer R01CA195586↗
  6. Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer R44CA224619↗
  7. MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases R44DK117472↗
  8. Development of Metabolically Active Linkers (MALs) to Improve Diagnostic and Radiotherapeutic HPMA Copolymers P20GM103480↗
  9. Novel Combination Therapy Against Pancreatic Cancer R21CA156037↗

Closest collaborators

The 25 strongest of 145 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 46 shared papers, 3 shared grants, 2011–2026 · strength 6.70
  2. Shailendra Kumar Gautam · 14 shared papers, 2017–2026 · strength 2.12
  3. Sushil Kumar K · 20 shared papers, 2011–2024 · strength 2.07
  4. Jered C Garrison · 2 shared grants, 2015–2026 · strength 1.47
  5. Moorthy Palanimuthu Ponnusamy · 14 shared papers, 2011–2025 · strength 1.45
  6. Kavita B. Mallya · 10 shared papers, 2013–2025 · strength 1.26
  7. Satyanarayana Rachagani · 16 shared papers, 2011–2024 · strength 1.25
  8. Lynette M. Smith · 11 shared papers, 2011–2026 · strength 1.09
  9. Michael Anthony Hollingsworth · 5 shared papers, 1 shared grant, 2015–2026 · strength 1.01
  10. Balaji Narasimhan · 4 shared papers, 1 shared grant, 2018–2026 · strength 1.01
  11. Parthasarathy Seshacharyulu · 8 shared papers, 2012–2025 · strength 0.86
  12. Aliasger K Salem · 2 shared papers, 1 shared grant, 2021–2026 · strength 0.81
  13. Joyce C. Solheim · 5 shared papers, 2018–2026 · strength 0.74
  14. Sanchita Rauth · 5 shared papers, 2021–2024 · strength 0.73
  15. Ravi Salgia · 1 shared grant, 2024 · strength 0.72
  16. Koelina Ganguly · 4 shared papers, 2022–2024 · strength 0.70
  17. Sukhwinder Kaur · 12 shared papers, 2011–2022 · strength 0.67
  18. Jesse L. Cox · 4 shared papers, 2022–2024 · strength 0.63
  19. Ashu Shah · 4 shared papers, 2022–2024 · strength 0.63
  20. Pranita Atri · 5 shared papers, 2020–2024 · strength 0.63
  21. Rama Krishna Nimmakayala · 5 shared papers, 2021–2023 · strength 0.62
  22. Sunidhi Jaiswal · 3 shared papers, 2024–2025 · strength 0.62
  23. Michael Bouvet · 3 shared papers, 2024–2025 · strength 0.62
  24. Namita Bhyravbhatla · 4 shared papers, 2022–2025 · strength 0.62
  25. Robert M. Hoffman · 3 shared papers, 2024–2025 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.